Phase III trial of remestemcel-L (MSC-100 mesenchymal stem cells) in adults with liver/gut graft-versus-host disease.
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2015
Price : $35 *
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Mesoblast
- 12 Feb 2015 According to a Mesoblast media release, JCR has filed for Japanese regulatory approval for JR-031 (Remestemcel-L) in acute graft-versus-host disease.
- 15 Sep 2014 New trial record